Sign In
Buy NCNA
$2.03
-0.0400 (-1.93%)
At Close: Jun 03, 2026
Why Is NuCana (NCNA) Stock Down 36% Today?
09:21am, Monday, 27'th Mar 2023
NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for inves
NuCana to Participate in Two Upcoming Investor Conferences
08:00am, Tuesday, 28'th Feb 2023
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will partici
NuCana: Pipeline And Major Gilead Litigation Progressing Nicely
04:30am, Sunday, 08'th Jan 2023
NuCana's market cap is not reflecting the potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. The UK and EU proceedings against Gilead for alleged years-long inf
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Monday, 21'st Nov 2022
NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks
11:18am, Wednesday, 05'th Oct 2022
NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
04:00pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)
01:35pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Wednesday, 28'th Sep 2022
NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)
11:17am, Wednesday, 28'th Sep 2022
The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
07:42am, Friday, 23'rd Sep 2022 Benzinga
Gainers
Spero Therapeutics, Inc. (NASDAQ: SPRO) shares jumped 167.7% to close at $2.20 on Thursday after the company announced it has entered into an exclusive license agreement with GSK for Spero's
NuCana: An Intriguing 'Sum Of The Parts' Story
03:40pm, Thursday, 22'nd Sep 2022
Today, we revisit a small oncology development outfit called NuCana plc for the first time in a year-and-a-half. NuCana plc has early/mid-stage assets in development as well as the chance of a signifi
NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
02:45pm, Monday, 12'th Sep 2022 GlobeNewswire Inc.
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors
NuCana to Participate in Citi's 17th Annual BioPharma Conference
12:00pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference.
NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update
08:01pm, Wednesday, 17'th Aug 2022 GlobeNewswire Inc.
Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023
This Asset Management Stock Is Trading Higher By More Than 45%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
04:07pm, Wednesday, 27'th Jul 2022 Benzinga
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 67.8% to $3.4390. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Children's Hospital Med
